证券之星消息，12月19日医疗美容板块较上一交易日上涨2.13%，爱美客领涨。当日上证指数报收于 3890.45，上涨0.36%。深证成指报收于13140.22，上涨0.66%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 145.80 | 2.81% | 4.06万 | | 5.8716 | | 920982 | 锦波生物 | 251.98 | 1.60% | 1.33万 | | 3.31亿 | | 000615 | *ST美谷 | 4.11 | 1.48% | 7.03万 | | 2875.42万 | | 688363 | 华熙生物 | 44.18 | 1.28% | 3.23万 | | 1.43亿 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入（元） 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | ...

从资金流向上来看，当日医疗美容板块主力资金净流入6532.5万元，游资资金净流出1191.11万元，散户 资金净流出5341.39万元。医疗美容板块个股资金流向见下表： 证券之星消息，12月16日医疗美容板块较上一交易日上涨0.98%，爱美客领涨。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 140.56 | 2.02% | 4.62万 | 6.53 Z | | 688363 | 华熙生物 | 43.29 | -0.07% | 3.98万 | 1.74亿 | | 920982 | 锦波生物 | 262.15 | -0.32% | 1.66万 | 4.44 Z | | 000615 | *ST美谷 | 4.09 | -1.45% | 5.75万 | 2369.06万 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010 ...

关于变更向不特定合格投资者公开发行股票并在北京证券交易所上市 持续督导、2025年度向特定对象发行股票保荐代表人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 山西锦波生物医药股份有限公司（以下简称"公司"）于2025年12月12日收到 保荐机构中信证券股份有限公司（以下简称"中信证券"）《关于更换保荐代表人 的函》，具体情况如下： 证券代码：920982 证券简称：锦波生物 公告编号：2025-183 山西锦波生物医药股份有限公司 中信证券作为公司向不特定合格投资者公开发行股票并在北京证券交易所上市 项目及2025年度向特定对象发行股票项目的保荐机构，其中，鉴于向不特定合格投 资者公开发行股票并在北京证券交易所上市项目处于法定持续督导期间，保荐机构 尚需履行持续督导义务，持续督导保荐代表人为邓俊、姚曜；2025年度向特定对象 发行股票项目的保荐代表人为邓俊、姚曜。现因原保荐代表人姚曜工作变动原因， 不再负责公司持续督导工作及本次向特定对象发行股票的保荐工作。为保证公司持 续督导工作及本次向特定 ...

Trading Volume and Market Activity - On December 12, the total trading volume of individual stocks on the Beijing Stock Exchange reached 1.134 billion shares, with a total transaction value of 26.973 billion yuan, a decrease of 1.332 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 143 stocks closed higher, accounting for 50% of the total, while 139 stocks closed lower [1] - The stocks with the highest closing gains included Chuangyuan Xinke, Changfu Co., and Caneng Electric Power, which rose by 14.80%, 11.38%, and 11.29% respectively [1] Stock Performance Highlights - The stocks with the highest transaction values included Jinbo Biological, Xingtou Measurement Control, and Tianli Composite, with transaction values of 1.045 billion yuan, 869 million yuan, and 862 million yuan respectively [1] - A total of 76 stocks had transaction values exceeding 10 million yuan, indicating significant trading activity [1] - The highest turnover rates were observed in stocks such as Dapeng Industrial, Jingchuang Electric, and Guangdao Tui, with turnover rates of 70.76%, 45.80%, and 41.72% respectively [1] Price Movements - The stock Guangdao Tui experienced the largest decline, dropping by 21.09%, followed by Longzhu Technology and Henghe Co., which fell by 6.56% and 6.53% respectively [1] - The closing prices of notable stocks included Jinbo Biological at 275.50 yuan, Tianli Composite at 60.84 yuan, and Chuangyuan Xinke at 31.80 yuan [1][2]

证券时报·数据宝统计显示，锦波生物今日收盘价为275.50元，上涨9.02%，日换手率为7.01%，成交额 为10.40亿元，近5日该股累计上涨20.67%。 据天眼查APP显示，山西锦波生物医药股份有限公司成立于2008年03月28日，注册资本11506.534万人 民币。（数据宝） 锦波生物（920982）12月12日大宗交易平台出现一笔成交，成交量1.46万股，成交金额478.88万元，大 宗交易成交价为328.00元，相对今日收盘价溢价19.06%。该笔交易的买方营业部为中信证券股份有限公 司大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生6笔大宗交易，合计成交金额为3240.88万元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | （%） | | | | 1.46 | 478.88 | 328.00 | 19.06 | 中信证券股份有限公司 大连高新园区证券营 ...

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing above the annual line, indicating a potential bullish trend in the market [1] Group 1: Market Performance - As of 13:59 today, the Shanghai Composite Index stands at 3888.05 points, with a change of 0.38% [1] - The total trading volume of A-shares today reached 1,628.31 billion yuan [1] Group 2: Stocks Breaking Annual Line - A total of 135 A-shares have surpassed the annual line today, with notable stocks including Jiusheng Electric, Shifeng Culture, and Xilong Science, which have deviation rates of 10.24%, 6.95%, and 6.26% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Xiying Technology, Sifang Technology, and Yuyue Medical [1] Group 3: Deviation Rate Rankings - The top three stocks with the highest deviation rates are: - Jiusheng Electric (11.21% increase, latest price 19.44 yuan, deviation rate 10.24%) [1] - Shifeng Culture (9.99% increase, latest price 21.79 yuan, deviation rate 6.95%) [1] - Xilong Science (10.00% increase, latest price 9.35 yuan, deviation rate 6.26%) [1] - Other notable stocks with significant increases include Tiandi Digital (8.20% increase) and Yunlu Co. (6.11% increase) [1]

Core Viewpoint - As of December 11, the total margin financing and securities lending balance on the Beijing Stock Exchange reached 7.709 billion yuan, marking an increase of 135 million yuan from the previous trading day, with financing balance also increasing for two consecutive trading days [1] Financing and Margin Data - The financing balance on December 11 was 7.709 billion yuan, up 135 million yuan from the previous day, while the securities lending balance was 23.55 thousand yuan, an increase of 320 yuan [1] - The stocks with the highest financing balances included Jinbo Biological (395 million yuan), Better Ray (355 million yuan), and Shuguang Digital Innovation (349 million yuan) [1] - The average financing balance as a percentage of market capitalization for these stocks was 1.38%, with the highest ratios seen in Audiwei (4.56%), Haidar (4.27%), and Taikai Ying (3.73%) [1] Sector Performance - In terms of industry, the most concentrated sectors for net financing purchases over one million yuan were power equipment (14 stocks), machinery (12 stocks), and computers (8 stocks) [2] - On December 11, stocks with net financing purchases over one million yuan saw an average increase of 4.56%, with notable gainers including Tianli Composite (30.00%), Dapeng Industrial (25.85%), and Fujida (13.42%) [2] - The average turnover rate for stocks with net financing purchases over one million yuan was 5.59%, with Dapeng Industrial (75.91%), Changfu Shares (21.04%), and Caneng Power (19.51%) leading in turnover [2] Notable Stocks - The stocks with the largest increases in financing balance on December 11 included Better Ray (354.57 million yuan, +1.78 million yuan), Fujida (85.89 million yuan, +1.045 million yuan), and Dapeng Industrial (19.38 million yuan, +914.81 thousand yuan) [2][3] - Other significant stocks with increased financing balances included Changfu Shares, Jinbo Biological, and Gebijia, with net purchases also recorded for these companies [1][2] Summary of Stock Movements - The stocks with the highest net financing purchases on December 11 were led by Better Ray (17.78 million yuan), followed by Fujida (10.45 million yuan) and Dapeng Industrial (9.14 million yuan) [1][2] - Conversely, the stocks with the highest net financing sales included Chenguang Cable (-13.28 million yuan), Kaitai Shares (-5.77 million yuan), and Tongli Shares (-5.66 million yuan) [1]

据天眼查APP显示，山西锦波生物医药股份有限公司成立于2008年03月28日，注册资本11506.534万人 民币。（数据宝） 12月11日锦波生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | （%） | | | | 2.00 | 638.00 | 319.00 | 26.24 | 中信证券股份有限公司 大连高新园区证券营业 | 华泰证券股份有限公司 南京长江路证券营业部 | | | | | | 部 | | （文章来源：证券时报网） 锦波生物（920982）12月11日大宗交易平台出现一笔成交，成交量2.00万股，成交金额638.00万元，大 宗交易成交价为319.00元，相对今日收盘价溢价26.24%。该笔交易的买方营业部为中信证券股份有限公 司大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生5笔大宗交易，合计成交金额为2762.00万元。 证券时报·数 ...

证券时报·数据宝统计显示，今日可交易北交所个股中，收盘股价上涨的有94只，占可交易个股的 32.98%，收盘涨幅居前的有凯德石英、天力复合、田野股份，分别上涨12.19%、7.78%、6.22%。收盘 股价下跌的有186只，跌幅居前的有曙光数创、惠丰钻石、吉林碳谷等，分别下跌7.98%、6.11%、 5.62%。 成交方面，全天成交额超亿元的股票共有31只，成交额居前的北交所股票有锦波生物、星图测控、曙光 数创等，成交额分别为4.43亿元、4.31亿元、4.10亿元。 股票活跃度来看，今日可交易的北交所个股中，换手率超10%的有12只，其中，2股换手率超20%，换 手率在5%~10%之间的有23只，换手率在1%~5%之间的有204只。全天换手率居前的股票有大鹏工业、 精创电气、朱老六等，换手率分别为38.02%、22.52%、17.95%。（数据宝） 北交所个股今日成交明细 | 代码 | 简称 | 收盘价（元） | 涨跌幅（%） | 换手率（%） | 成交额（万元） | | --- | --- | --- | --- | --- | --- | | 920982 | 锦波生物 | 245.95 | 5.42 ...

Core Insights - The "light medical beauty" market in China has rapidly penetrated modern life, with treatments like photon rejuvenation and water light needles becoming accessible during short breaks, reflecting a shift in consumer behavior and preferences [1][3][4] - The market has evolved significantly over the past decade, with a growing user base and increasing market transparency, leading to a projected user scale of 31.05 million by 2025 [1][2] - The industry is experiencing consolidation, with small institutions facing challenges due to increased competition from new players like New Oxygen and JD Health, indicating a trend towards chain operations and larger entities [2][12] Market Growth and Trends - The user scale of China's light medical beauty market reached 23.54 million in 2023, with expectations to grow to 31.05 million by 2025 [1] - The medical beauty market size is projected to increase from 227.4 billion yuan in 2021 to 364 billion yuan by 2025, with light medical beauty accounting for 53.3% of the market [1] - The consumer demographic has expanded from a niche market to a broader age range, including Z generation to individuals over 40, indicating a shift towards a more inclusive consumer base [5][12] Consumer Behavior and Preferences - There is a notable shift in consumer preferences from "internet celebrity faces" to more natural aesthetics, with 78% of consumers seeking natural results [4][5] - Male consumers are emerging as a significant growth segment, with their share in the medical beauty market increasing from 14% to 29% between 2022 and 2025 [5][6] - Consumers are increasingly prioritizing quality and personalized aesthetic design over mere procedural outcomes, reflecting a maturation in consumer awareness [4][10] Product and Service Evolution - The market has seen a shift in dominant products, with botulinum toxin and hyaluronic acid remaining the leading choices, while regenerative materials are gaining traction [6][7] - Regenerative materials, such as polylactic acid and recombinant collagen, are being introduced, but experts believe hyaluronic acid will maintain its dominant position due to its established safety and effectiveness [7][8] - The price of medical beauty services is becoming more transparent, with significant reductions in costs for treatments like photon rejuvenation, making them more accessible to a wider audience [10][11] Industry Dynamics and Future Outlook - The medical beauty industry is undergoing significant restructuring, with a high turnover rate of institutions and a trend towards professional consolidation [12][13] - Future industry developments are expected to focus on chain operations, involvement of listed companies, and participation of state-owned capital, enhancing trust and operational efficiency [13][14] - The market is anticipated to continue evolving towards a dual-track model of professionalization and market segmentation, with large chains dominating standardized treatments while niche clinics focus on personalized services [14]